Constructing a Prognostic Model for Bladder Cancer Via Long Non-Coding RNA Signatures

By Patrick Daly - Last Updated: February 11, 2022

According to a study published in Frontiers in Oncology, the role of N6-methyladenosine (m6A)-related long non-coding RNAs (lncRNAs) in the prognosis of patients with bladder cancer (BC) is unclear. Researchers, led by Kang Chen from the Department of Urology at the Renmin Hospital of Wuhan University in Wuhan, China, evaluated the m6A-related lncRNAs in samples from patients with BC and identified 14 m6A-related lncRNAs that were used to develop a prognostic signature cluster, which the study’s team termed “m6A-LPS.”

The BC samples used in the analysis were collected from The Cancer Genome Atlas (TCGA) project database. A total of 50 m6A-related lncRNAs that were linked with BC prognosis were screened out from the samples and divided into two clusters via consensus cluster analysis. According to the report, the lncRNAs in cluster two were associated with a poorer prognosis as well as increased PD-L1 expression. Furthermore, gene set enrichment analysis (GSEA) demonstrated tumor-related pathways in cluster two.

Using least absolute shrinkage and selection operator (LASSO), Cox regression, univariate and multivariate Cox regression, and receiver operating characteristic (ROC) analyses, the investigators selected 14 m6A-related lncRNAs to construct the m6A-LPS model. The study’s authors relayed that the model was a “valuable independent prognostic factor,” and they also highlighted that the model’s risk scores were positively correlated with the immune score, PD-L1 expression, and immune cell subtype infiltration seen in the BC samples.

The contributors concluded that their study “illustrates the role of m6A-related lncRNAs in BC.” Additionally, given the associations between the lncRNA cluster and BC characteristics, the authors theorized that “the m6A-LPS may be an important regulatory target of the tumor microenvironment (TME) in BC.”